Literature DB >> 8576934

Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium.

S C Tyagi1, S G Kumar, J Banks, W Fortson.   

Abstract

Matrix metalloproteinases (MMP) are present in the latent form in normal myocardium. To examine the stringent balance between MMP and tissue inhibitor of metalloproteinase (TIMP) and to determine whether MMP are secreted simultaneously and in co-ordination with their inhibitors, we analysed MMP and TIMP by immunological, isolation by gel-permeation and affinity chromatography, and enzymatic assays in tissues and extracts. Using antibodies to MMP-1 and TIMP-1, we found strong in situ staining of MMP-1 and TIMP-1 in tissues. The staining was uniform in the endo- and subendomyocardium as well as in the interstitial space. TIMP-1 was present wherever MMP-1 was localized. From the tissue extract, proteins were separated on a gel-filtration column (Sephacryl S-200) and analysed for MMP and TIMP activity by zymography as well as by using succinyl-Gly-Pro-Leu-Gly-Pro-4-amido-7-methyl coumarin (Suc-GPLGP-AMC) as a selective fluorogenic substrate for collagenase. TIMP and MMP were further purified on collagen-Sepharose affinity column. The results indicated that MMP activity was co-eluted with TIMP activity. MMP-1, MMP-2 and TIMP-1 were further analysed by Northern blot for mRNA levels in the heart, skin, lung, liver and kidney. Results suggested co-expression of MMP-1 and TIMP-1 at the transcription level in all tissues. The level of MMP-2 mRNA was specifically higher in the heart tissue, which suggests a role of MMP-2 in the integrity of cardiovascular structure. The study indicated that myocardium as well as other tissue have an endogenous inhibitory system, suggesting that the MMPs activity is co-ordinated by their inhibitors at both the gene and protein levels. Furthermore, MMP and TIMP were co-expressed and were tightly regulated in maintaining the architecture of the interstitial tissue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576934     DOI: 10.1016/s0022-2828(95)91443-9

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  13 in total

1.  Extracellular matrix alterations in cardiomyopathy: The possible crucial role in the dilative form.

Authors:  V I Kapelko
Journal:  Exp Clin Cardiol       Date:  2001

Review 2.  Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

Authors:  Merry L Lindsey; Rogelio Zamilpa
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

3.  Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction.

Authors:  M Fassbach; B Schwartzkopff
Journal:  Z Kardiol       Date:  2005-05

4.  Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis.

Authors:  I Friehs; R E Margossian; A M Moran; H Cao-Danh; M A Moses; P J del Nido
Journal:  Basic Res Cardiol       Date:  2005-12-23       Impact factor: 17.165

5.  Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts.

Authors:  S C Tyagi; S E Campbell; H K Reddy; E Tjahja; D J Voelker
Journal:  Mol Cell Biochem       Date:  1996-02-09       Impact factor: 3.396

6.  Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction.

Authors:  S Hirohata; S Kusachi; M Murakami; T Murakami; I Sano; T Watanabe; I Komatsubara; J Kondo; T Tsuji
Journal:  Heart       Date:  1997-09       Impact factor: 5.994

7.  Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine.

Authors:  Raffaele Altara; Marco Manca; Ramzi Sabra; Assaad A Eid; George W Booz; Fouad A Zouein
Journal:  Heart Fail Rev       Date:  2016-01       Impact factor: 4.214

8.  Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients.

Authors:  F Picard; M Brehm; M Fassbach; B Pelzer; S Scheuring; P Küry; B E Strauer; B Schwartzkopff
Journal:  Clin Res Cardiol       Date:  2006-04-03       Impact factor: 6.138

9.  Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease.

Authors:  Dong Fan; Abhijit Takawale; Jiwon Lee; Zamaneh Kassiri
Journal:  Fibrogenesis Tissue Repair       Date:  2012-09-03

Review 10.  Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers.

Authors:  Camelia R Ban; Stephen M Twigg
Journal:  Vasc Health Risk Manag       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.